Cyclin-dependent kinase-like 5 (CDKL5)

Cyclin-dependent kinase-like 5 is a serine/threonine protein kinase encoded by the CDKL5 gene on the X chromosome[1][3][4]. The enzyme is critical for early brain development, neural maturation, dendritic spine signaling, and synaptic function[1][3][4]. Unlike canonical cyclin-dependent kinases, CDKL5 does not require binding to cyclins for its activation[2][3]. Mutations in CDKL5 lead to CDKL5 deficiency disorder (CDD), a severe neurodevelopmental syndrome presenting with early-onset, intractable epilepsy, developmental delay, motor dysfunction, and intellectual disability[3][4]. The protein regulates nuclear and cytoplasmic processes, including transcriptional regulation via phosphorylation of MeCP2 and HDAC4, chromatin remodeling, and synapse structure via substrates such as NGL-1 and PSD-95[1][3][4]. While the only approved therapy specifically for CDKL5 deficiency is ganaxolone (working through GABAergic modulation), broader kinase-targeted drug discovery is ongoing[1][3].

Other names

Serine/threonine-protein kinase CDKL5STK9Epileptic encephalopathy, early infantile, 2 (EIEE2)

Positive allosteric modulation of GABA\(_A\) receptors (for ganaxolone, indirect mechanism related to downstream effects of CDKL5 deficiency) Research into CDKL5-activating drugs or kinase-activating therapies is ongoing, but no other direct small-molecule modulators are clinically approved[1][3].